Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical Advancements by 20+ Global Leaders - DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals, Precision Biosciences, Prothena, Caelum Biosciences,

With Cardiac amyloidosis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Cardiac amyloidosis pipeline comprises 20+ pharmaceutical and biotech companies actively developing 100+ therapeutic candidates targeting Cardiac amyloidosis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Cardiac amyloidosis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Cardiac amyloidosis Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Cardiac amyloidosis Drug Development @ https://www.delveinsight.com/report-store/cardiac-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Cardiac amyloidosis Pipeline Report

DelveInsight's Cardiac amyloidosis pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Cardiac amyloidosis treatment.
In March 2025, the FDA approved Vutrisiran (Amvuttra), developed by Alnylam Pharmaceuticals, for the treatment of ATTR-CM.
In November 2024, the FDA approved Acoramidis (brand name Attruby), developed by BridgeBio Pharma, for treating both wild-type and hereditary ATTR-CM.
Key Cardiac amyloidosis companies such as Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals, Precision Biosciences, Prothena, Caelum Biosciences, Zentalis Pharmaceuticals, Attralus, and others are evaluating new drugs for Cardiac amyloidosis to improve the treatment landscape.
Promising Cardiac amyloidosis pipeline therapies in various stages of development include Acoramidis, NTLA-2001, and others.

Cardiac amyloidosis Overview:

Cardiac amyloidosis is a major cause of restrictive cardiomyopathy and often presents as rapidly worsening diastolic dysfunction in a non-dilated heart. Despite its impact, it remains frequently underdiagnosed. Diagnosis requires a high index of suspicion, with cardiac imaging playing a central role.

Amyloid deposits affect the heart in various ways. Interstitial buildup increases ventricular wall thickness and stiffness, leading to diastolic dysfunction. In AL amyloidosis, deposits in small blood vessels may cause angina or, in rare cases, heart attacks. Amyloid accumulation in the atria can create structural changes that promote atrial fibrillation and raise the risk of atrial clots and embolism, even without arrhythmia. Additionally, toxic light chains can damage heart muscle cells through oxidative stress.

Download the Cardiac amyloidosis sample report to know in detail about the Cardiac amyloidosis treatment market @ https://www.delveinsight.com/sample-request/cardiac-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cardiac amyloidosis Pipeline Analysis
The Cardiac amyloidosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Cardiac amyloidosis Market.

Categorizes Cardiac amyloidosis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Cardiac amyloidosis drugs under development based on:

Stage of development

Cardiac amyloidosis Route of administration

Target receptor

Monotherapy vs. combination therapy

Cardiac amyloidosis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Cardiac amyloidosis Licensing agreements

Funding and investment activities supporting future Cardiac amyloidosis market advancement.

Unlock key insights into emerging Cardiac amyloidosis therapies and market strategies here: https://www.delveinsight.com/report-store/cardiac-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cardiac amyloidosis Emerging Drugs

Acoramidis: Eidos Therapeutics

Eidos Therapeutics is developing Acoramidis (AG10), a small molecule designed at Stanford University to strongly stabilize transthyretin (TTR). It mimics the protective T119M TTR variant, which enhances protein stability about 40 times more than the native form by forming unique central bonds. In preclinical studies, Acoramidis was shown to bind to the same central sites on TTR tetramers where T119M stabilizing bonds occur, a mechanism believed to drive its strong stabilizing effect.

NTLA-2001: Intellia Therapeutics

NTLA-2001 is the first CRISPR/Cas9-based therapy candidate to be delivered systemically for precise gene editing in humans. It targets liver cells to deactivate the TTR gene, aiming to lower the production of misfolded TTR protein that accumulates in tissues and leads to the severe, often life-threatening complications of ATTR amyloidosis.

Cardiac amyloidosis Pipeline Therapeutic Assessment

Cardiac amyloidosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Cardiac amyloidosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cardiac amyloidosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Cardiac amyloidosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Cardiac amyloidosis therapies and key Cardiac amyloidosis companies: https://www.delveinsight.com/sample-request/cardiac-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Cardiac amyloidosis Current Treatment Patterns
4. Cardiac amyloidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cardiac amyloidosis Late-Stage Products (Phase-III)
7. Cardiac amyloidosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cardiac amyloidosis Discontinued Products
13. Cardiac amyloidosis Product Profiles
14. Cardiac amyloidosis Key Companies
15. Cardiac amyloidosis Key Products
16. Dormant and Discontinued Products
17. Cardiac amyloidosis Unmet Needs
18. Cardiac amyloidosis Future Perspectives
19. Cardiac amyloidosis Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Cardiac amyloidosis pipeline reports offerings: https://www.delveinsight.com/report-store/cardiac-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.